Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California

J Clin Microbiol. 2010 Oct;48(10):3779-81. doi: 10.1128/JCM.01236-10. Epub 2010 Aug 11.

Abstract

To assess the clinical impact of a molecular beacon (MB) assay that detects multidrug-resistant tuberculosis (MDR TB), we retrospectively reviewed records of 127 MDR TB patients with and without MB testing between 2004 and 2007. Use of the MB assay reduced the time to detection and treatment of MDR TB.

Publication types

  • Evaluation Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • California
  • Early Diagnosis
  • Female
  • Humans
  • Male
  • Microbial Sensitivity Tests / methods
  • Middle Aged
  • Molecular Diagnostic Techniques / methods*
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / genetics
  • Mycobacterium tuberculosis / isolation & purification*
  • Retrospective Studies
  • Time Factors
  • Tuberculosis, Multidrug-Resistant / diagnosis*
  • Tuberculosis, Multidrug-Resistant / microbiology*

Substances

  • Antitubercular Agents